Zobrazeno 1 - 10
of 89
pro vyhledávání: '"R. J. Fram"'
Autor:
R. J. Fram, J. Wilson, G. Strauss, Joel S. Greenberger, Sidney P. Kadish, D. Silver, P. Egan, Robert A. Lew, M. Liepman, Thomas J. Fitzgerald, D. Sherman, Lawrence D. Recht
Publikováno v:
American Journal of Clinical Oncology. 13:125-131
Thirty patients with histologically verified malignant supratentorial gliomas were treated with a preirradiation chemotherapy protocol consisting of two courses of intracarotid (i.c.) CDDP, 90 mg/m2, followed by i.v. BCNU, 200 mg/m2. Side effects fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::390de64858d0a7561a8fc12494fbd41a
https://doi.org/10.1097/00000421-199004000-00008
https://doi.org/10.1097/00000421-199004000-00008
Autor:
H, Hamdalla, R J, Fram
Publikováno v:
Medicine and health, Rhode Island. 83(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a39ce5f6f097610092baf11bf0d195f2
https://pubmed.ncbi.nlm.nih.gov/10821011
https://pubmed.ncbi.nlm.nih.gov/10821011
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
Autor:
B A, Conley, M J, Egorin, N, Tait, D M, Rosen, E A, Sausville, G, Dover, R J, Fram, D A, Van Echo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(3)
Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies. Tributyrin, a triglyceride with butyrate molecules esterified at the 1, 2, and 3 positions, induces differentiation and/or growth inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b2e42c324178f52b94aa9edca9afefad
https://pubmed.ncbi.nlm.nih.gov/9533530
https://pubmed.ncbi.nlm.nih.gov/9533530
Autor:
D, Glover, A, Lipton, A, Keller, A A, Miller, S, Browning, R J, Fram, S, George, K, Zelenakas, R S, Macerata, J J, Seaman
Publikováno v:
Cancer. 74(11)
Treatment of the symptoms of bone metastases currently involves the use of narcotic medication, radiation therapy, or hormonal therapy. Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5fe76387cd30cb213c51ccef6ad8c77a
https://pubmed.ncbi.nlm.nih.gov/7525038
https://pubmed.ncbi.nlm.nih.gov/7525038
Publikováno v:
Cancer research. 50(1)
To study mechanisms underlying resistance to cis-diamminedichloroplatinum (II) (cis-DDP) we have induced resistance to this agent in BE human colon carcinoma cells. A 5-fold increase in the IC50 of resistant compared to sensitive cells was noted as a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::25f68a0d5cecdf4679c26df67a993b7e
https://pubmed.ncbi.nlm.nih.gov/2293559
https://pubmed.ncbi.nlm.nih.gov/2293559
Autor:
A. Qin, Alain C. Mita, Amita Patnaik, John Sarantopoulos, A. Ricart, Monica M. Mita, J. Watermill, Anthony W. Tolcher, R. J. Fram, K. K. Sankhala
Publikováno v:
Journal of Clinical Oncology. 25:3062-3062
3062 Background: HuC242-DM4 is a novel, targeted anti-cancer agent in development for the treatment of CanAg-expressing tumors such as carcinomas of the colon and pancreas. The compound is formed by the conjugation of the potent cytotoxic maytansinoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e8f5db0724fa3f2481a610a310f6e2e
https://doi.org/10.1200/jco.2007.25.18_suppl.3062
https://doi.org/10.1200/jco.2007.25.18_suppl.3062
Autor:
Frank V. Fossella, P. Fidias, J. McCann, R. Raju, Anthony W. Tolcher, Miguel A. Villalona-Calero, R. J. Fram, R. Guild, S. Zildjian
Publikováno v:
Journal of Clinical Oncology. 25:18084-18084
18084 Background: HuN901-DM1, a humanized antibody-maytansinoid immunoconjugagte, binds to CD56 which is expressed in almost all cases of SCLC as well as in other small cell carcinomas (SCC), neuroendocrine carcinomas, and multiple myeloma. The immun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d76b01833776be0e45e8c9b5b7c7a0e
https://doi.org/10.1200/jco.2007.25.18_suppl.18084
https://doi.org/10.1200/jco.2007.25.18_suppl.18084
Autor:
R. J. Fram, S. Sarantopolus, J. Watermill, A. Ricart, Alain C. Mita, Anthony W. Tolcher, S. Zildjian, Amita Patnaik, Monica M. Mita, J. Rodon
Publikováno v:
European Journal of Cancer Supplements. 4:66
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02efc9ca7e9411a343f2b2b68452e644
https://doi.org/10.1016/s1359-6349(06)70217-8
https://doi.org/10.1016/s1359-6349(06)70217-8
Publikováno v:
Molecular pharmacology. 28(1)
Because cytotoxicity by an alkylating agent such as N-methyl-N'-nitrosoguanidine is markedly increased in adenine methylase-deficient dam-3 Escherichia coli, it was of interest to assess whether mismatch repair was similarly important in the repair o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4a11d1cf7f1854862eb45ed7fb392d23
https://pubmed.ncbi.nlm.nih.gov/3894930
https://pubmed.ncbi.nlm.nih.gov/3894930
Publikováno v:
Cancer research. 47(13)
Prior reports demonstrated more than additive cytotoxic effects of cis-diamminedichloroplatinum(II) (CDDP) and 1-beta-D-arabinofuranosylcytosine (ara-C) in LoVo colon carcinoma cells. We have extended these findings by analyzing mechanisms that may u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c246dcc73f1bad58ab75a980d8a7fc44
https://pubmed.ncbi.nlm.nih.gov/3107809
https://pubmed.ncbi.nlm.nih.gov/3107809